Rygiel Katarzyna*

Department of Environmental Medicine and Epidemiology, Medical University of Silesia (SUM), Zabrze, Poland

*Corresponding Author: Rygiel Katarzyna, Department of Environmental Medicine and Epidemiology, Medical University of Silesia (SUM), Zabrze, Poland.

Received: February 23, 2018; Published: March 23, 2018

Citation: Rygiel Katarzyna. “How can we Manage Hypertriglyceridemia? Practical Insights to Interdisciplinary Approach to Patients”. Acta Scientific Pharmaceutical Sciences 2.4 (2018).

Abstract

  Hypertriglyceridemia, defined as elevated triglyceride (TG) levels (≥ 150 mg/dL; ≥ 1.7 mmol/L) is related with augmented risk of cardiovascular disease (CVD), and severe hypertriglyceridemia (characterized by TG levels ≥ 500 mg/dL; ≥ 5.6 mmol/L) represents risk factor for acute pancreatitis. Importantly, TG concentration in plasma illustrates the total amount of TG, contained in TG-rich lipoproteins (TRLs), such as: very low-density lipoproteins (VLDL), chylomicrons, and their remnants, TRLs can accelerate atherosclerotic processes through several mechanisms, including proinflammatory and procoagulant actions, as well as cholesterol deposition in the arterial walls. Despite a substantial research evidence in this area, low-density lipoprotein (LDL) cholesterol still represents the main therapeutic target for cardiovascular (CV) risk reduction. Several studies have shown that elevated TG levels are independently related with higher rate of CV events, even among patients receiving therapy with statins.

Keywords: Hypertriglyceridemia; Cardiovascular (CV); Coronary Heart Disease (CHD); Triglyceride (TG); Prevention; Disease Management

Copyright: © 2018 Rygiel Katarzyna. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.